1-3 of 3
Thomas M. Paul
Close
Sort by
Journal Articles

Combined Autophagy and Proteasome Inhibition for Multiple Myeloma: Final Results of a Phase 1 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Patients with Relapsed or Refractory Myeloma

Dan T. Vogl, MD, MSCE, Edward A. Stadtmauer, MD, James Bradner, MD, Lisa Davis, PharmD, Thomas M. Paul, Emma C. Scott, MD, Charles W. Nichols, MD, David L. Porter, MD, Martin Carroll, MD, Janeen Kaplan, Gayle Mallon, Cezary R. Swider, Patricia A. Mangan, Brenda K. Shelly, Ravi K. Amaravadi, MD
Journal: Blood
Blood (2011) 118 (21): 1869.
https://doi.org/10.1182/blood.V118.21.1869.1869
Published: 2011
Journal Articles

Effect of Pharmacokinetic Variability on the Toxicity and Efficacy of High-Dose Melphalan for Multiple Myeloma

Dan T. Vogl, MD, MSCE, Eric Stoopler, DMD, Lisa Davis, PharmD, Thomas M. Paul, German Salazar, DDS, Maria Raguza-Lopez, David L. Porter, MD, Selina M. Luger, MD, Edward A. Stadtmauer, MD
Journal: Blood
Blood (2010) 116 (21): 1349.
https://doi.org/10.1182/blood.V116.21.1349.1349
Published: 2010
Journal Articles

Effect of Obesity and Renal Insufficiency On Toxicity of High-Dose Melphalan for Multiple Myeloma.

Dan T. Vogl, Thomas M. Paul, Eric Stoopler, German Salazar, Lisa Davis, Shiv Kapoor, Babette Zemel, Mark Yudkoff, Gail Jackson, Lisa Basel-Brown, Kenneth Rockwell, Evgueni Daikhin, Cezary R. Swider, John Washington, Maria Raguza-Lopez, Thomas Tenhave, Edward A. Stadtmauer
Journal: Blood
Blood (2009) 114 (22): 1177.
https://doi.org/10.1182/blood.V114.22.1177.1177
Published: 2009